Workers' Comp Pharmacy Costs Are Rising Again, and Your Mod Will Show It
WCRI data shows workers' comp pharmacy costs per claim rose 24% since Q1 2022. Topical dispensing markups and CGRP migraine drugs are the new cost drivers, and they flow straight into your mod.
WCRI's 6th Edition drug trends study shows quarterly prescription payments per workers' comp claim rose 24% between Q1 2022 and Q1 2025, climbing from $51 to $63 at the median of 31 states (WCRI, 2025). The reversal is driven by physician-dispensed topicals and emerging CGRP migraine therapies. For contractors, rising pharmacy costs per claim increase incurred losses on the experience rating worksheet, pushing the mod higher across the two to three policy years those claims stay in the formula.
Pharmacy costs in workers' comp were supposed to be a solved problem. Opioid reforms worked. Formularies got tighter. From 2018 through early 2022, median drug spending per claim fell steadily, dropping from $67 to $51 per quarter across WCRI's (Workers Compensation Research Institute) 31 study states. Carriers moved on. Risk managers moved on.
They moved on too soon.
The 24% reversal in workers comp pharmacy costs
Between Q1 2022 and Q1 2025, quarterly prescription payments per medical claim rose 24% at the median, climbing from $51 back to $63 (WCRI Drug Trends, 6th Ed., 2025). That's not quite back to 2018 levels. But the trajectory has flipped, and the drivers aren't the ones most people associate with workers' comp drug spending.
Opioids now account for roughly 3% of prescription payments in the median state. The new cost drivers are topical medications dispensed through nontraditional channels and an emerging class of high-cost migraine therapies called CGRP (calcitonin gene-related peptide) antagonists. Neither was on most risk managers' watch lists five years ago.
Topicals and the dispensing channel gap
Dermatological agents remain the single largest drug cost category: 23% of prescription payments in the median state as of Q1 2025 (WCRI, 2025). In 12 of 31 study states, that share exceeds 30%. Pennsylvania hits 56%.
The cost isn't the medication itself. It's the channel. In 20 of 31 states, physician dispensing and delivery pharmacies together account for more than 70% of dermatological payments. Delivery pharmacies charge an average of $653 per prescription versus $136 at traditional retail (WCRI, 2025). That's a nearly five-to-one markup on the same class of drug.
The interstate variation tells the policy story. Minnesota pays roughly $14 per medical claim per quarter in prescription costs. Louisiana pays $353. A 25-fold spread across states operating under nominally similar workers' comp systems (WCRI, 2025).
States that fixed it, and one that made it worse
Georgia's Board of Workers' Compensation updated its fee schedule in April 2024 to cap reimbursement for topical medications. The result: dermatological payment shares dropped from a peak of 55% in early 2024 to 17% by Q1 2025 (WCRI, 2025). South Carolina implemented similar caps in 2022 and saw comparable declines. Both states proved that targeted fee schedule reform works. And works fast.
Florida took the judicial route. In February 2026, the First District Court of Appeal ruled that physicians cannot dispense medications directly to workers' comp patients under Florida Statute 440.13(3)(d) (Insurance Journal, Feb. 2026). Industry groups project $43 million in savings over five years (Florida Insurance Council, 2026). The legislature wrapped its session in March without reversing the decision.
Then there's New York. Per-claim prescription payments jumped 66%, the largest increase of any WCRI study state (WCRI, 2025). The culprit: higher-priced topicals designated as formulary drugs that don't require prior authorization. A formulary alone doesn't control costs when the pricing underneath it stays broken.
For Southeast contractors, the Georgia and South Carolina results are encouraging. Fee schedule reform in your state means those inflated topical charges don't hit your claims at the same levels they would in Pennsylvania or New York. But NCCI's (National Council on Compensation Insurance) experience rating formula uses the incurred losses your carrier reports. If your claims touch a state without those controls, the pharmacy costs flow straight onto your worksheet.
The CGRP wildcard
WCRI tracked migraine drugs as a separate category for the first time in this edition. In states above the 75th percentile, migraine medications now account for 10% to 26% of prescription payments (WCRI, 2025). Massachusetts saw a 19-percentage-point increase in migraine drug share between 2022 and 2025.
The driver is CGRP antagonist therapies: Aimovig, Ajovy, Emgality, and their peers. These run $600 to $1,200 per month per patient (Health-e-Systems, 2025). California added multiple CGRP medications to its workers' comp formulary in April 2026 for traumatic brain injury treatment, signaling broader adoption ahead (CWCI, May 2026).
CGRP drugs aren't a dispensing channel abuse problem. They're legitimate, expensive therapies entering claims at scale. That makes them harder to challenge on a claim-by-claim basis and more likely to persist as a severity driver. For construction, where head injuries and post-concussion symptoms are part of the risk profile, the trend matters.
What an audit would check
An audit examines whether pharmacy charges on each claim in the experience period are accurately reflected in the incurred totals reported to NCCI. It looks at whether nontraditional dispensing channels have inflated claim values beyond what the underlying injury warrants. The claims that distort a worksheet aren't catastrophic injuries. They're routine strains and lacerations where $1,200 in topicals sits next to a $400 office visit.
If you're a Southeast contractor and your per-claim severity has crept up without a clear injury pattern behind it, send us your NCCI worksheet and we'll review it for free.